Literature DB >> 24791969

Preemptive dexmedetomidine to prevent propofol injection pain in children.

J Yu1, Y Zhang, Y Lu, C Dong.   

Abstract

BACKGROUND: The incidence of propofol injection pain is high in children, but no methods have been found to suppress it completely. This study intends to evaluate the efficacy of dexmedetomidine-midazolam in preventing propofol injection pain in children.
METHODS: One-hundred ASA I patients, aged 3-12 years, weighing 15-53 kg, undergoing elective surgery were randomized into two groups of 50 each, using computer-generated random numbers. Normal saline 0.15 ml/kg in Group C or dexmedetomidine 0.6 μg/kg in Group D was infused IV over 10 min. Then midazolam 0.06 mg/kg was administered immediately; 2 min after aforementioned treatments in each group, all patients received propofol 2 mg/kg (propofol was mixed with lidocaine 1 mg/ml in Group C) at an average rate of 0.2 ml per 1 s. Another anesthesiologist, blind to the pretreatment, recorded the occurrence of injection pain using a four-graded pain scale: 1 = no pain (no reaction to injection), 2 = slight pain (minor verbal/facial response or motor reaction to injection), 3 = moderate pain (clear verbal/facial response or motor reaction to injection) and 4 = severe pain (the patient both complained of pain and withdrew the arm).
RESULTS: Forty (80 %) patients in Group C (control) had injection pain; however, none of patients in Group D had any injection pain. The total incidence of profol-induced pain in Group C was significantly higher (P < 0.01). There were no instances of bradycardia or low blood pressure with either treatment in this study.
CONCLUSIONS: Pretreatment with dexmedetomidine 0.6 μg/kg, then midazolam 0.06 mg/kg could suppress propofol injection pain in children.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24791969     DOI: 10.1007/s11845-014-1122-3

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  19 in total

1.  Premedication with intravenous dexmedetomidine-midazolam suppresses fentanyl-induced cough.

Authors:  J Yu; Y Lu; C Dong; H Zhu; R Xu
Journal:  Ir J Med Sci       Date:  2012-02-29       Impact factor: 1.568

2.  Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia.

Authors:  Aynur Akin; Adnan Bayram; Aliye Esmaoglu; Zeynep Tosun; Recep Aksu; Resul Altuntas; Adem Boyaci
Journal:  Paediatr Anaesth       Date:  2012-01-23       Impact factor: 2.556

3.  Does dexmedetomidine reduce the injection pain due to propofol and rocuronium?

Authors:  H Ayoğlu; H Altunkaya; Y Ozer; O Yapakçi; G Cukdar; I Ozkoçak
Journal:  Eur J Anaesthesiol       Date:  2007-01-23       Impact factor: 4.330

4.  Prevention of propofol-induced pain in children: pretreatment with small doses of ketamine.

Authors:  Guang-yi Zhao; Yao Guo; Shu-min Bao; Ling-xin Meng; Li-hong Zhang
Journal:  J Clin Anesth       Date:  2012-06       Impact factor: 9.452

5.  Propofol injection pain in children: a prospective randomized double-blind trial of a new propofol formulation versus propofol with added lidocaine.

Authors:  Y Nyman; K von Hofsten; A Georgiadi; S Eksborg; P A Lönnqvist
Journal:  Br J Anaesth       Date:  2005-05-13       Impact factor: 9.166

6.  Comparison of effects of dexmedetomidine-ketamine and dexmedetomidine-midazolam combinations in transurethral procedures.

Authors:  Emine Arzu Kose; Mehtap Honca; Erdal Yılmaz; Ertan Batislam; Alpaslan Apan
Journal:  Urology       Date:  2012-06       Impact factor: 2.649

Review 7.  Dexmedetomidine: pediatric pharmacology, clinical uses and safety.

Authors:  Felice Su; Gregory B Hammer
Journal:  Expert Opin Drug Saf       Date:  2010-08-18       Impact factor: 4.250

8.  A ketamine-propofol admixture does not reduce the pain on injection compared with a lidocaine-propofol admixture.

Authors:  Olfa Kaabachi; Olfa Chettaoui; Rami Ouezini; Ahmed Ben Abdelaziz; Rafii Cherif; Hannu Kokki
Journal:  Paediatr Anaesth       Date:  2007-08       Impact factor: 2.556

9.  High dose dexmedetomidine as the sole sedative for pediatric MRI.

Authors:  Keira P Mason; David Zurakowski; Steven E Zgleszewski; Caroline D Robson; Maureen Carrier; Paul R Hickey; James A Dinardo
Journal:  Paediatr Anaesth       Date:  2008-03-18       Impact factor: 2.556

10.  Prevention of propofol-induced pain in children: combination of alfentanil and lidocaine vs alfentanil or lidocaine alone.

Authors:  H J Kwak; S K Min; J S Kim; J Y Kim
Journal:  Br J Anaesth       Date:  2009-06-19       Impact factor: 9.166

View more
  5 in total

1.  Effect of dexmedetomidine for attenuation of propofol injection pain in electroconvulsive therapy: a randomized controlled study.

Authors:  Xiang Li; Chao-Jin Chen; Fang Tan; Jing-Ru Pan; Ji-Bin Xing; Qian-Qian Zhu; Zi-Qing Hei; Shao-Li Zhou
Journal:  J Anesth       Date:  2017-11-10       Impact factor: 2.078

2.  Dexmedetomidine as an adjuvant during general anesthesia.

Authors:  Shinju Obara
Journal:  J Anesth       Date:  2018-05-15       Impact factor: 2.078

3.  Efficacy of Pre-Treatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing Abortion or Curettage: A Prospective, Double-Blinded, Randomized and Placebo-Controlled Clinical Trial.

Authors:  Xuehai Guan; Ziyin Jiao; Xiaofang Gong; Huiyu Cao; Susu Liu; Hongmeng Lan; Xiaofang Huang; Yanmeng Tan; Bing Xu; Chengxin Lin
Journal:  Drug Des Devel Ther       Date:  2021-11-04       Impact factor: 4.162

4.  Effects and safety of magnesium sulfate on propofol-induced injection pain, a meta-analysis of randomized controlled trials.

Authors:  Mengzhu Li; Xiang Zhao; Lingling Zhang; Xiaoyin Niu; Ting Guo; Bowen Yang; Zhiqiang Liu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Esketamine prevents propofol-induced injection pain: Randomized controlled trial.

Authors:  Chaozhi Xu; Xiaotang Wei; Cuiwen Zhang; Xiaofang Huang; Hongmeng Lan; Yanping Xu; Xiaoyan Wu; Fuping Li; Xuehai Guan
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.